Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 181

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 181
---
 No. 11,708,423,
having an anticipated expiration date of March 26, 2039, including 186 days of patent term adjustment awarded by the USPTO;

EP Patent No. 3,519,441
(validated in the United Kingdom, France, Spain, Germany, and Italy), having an anticipated expiration date of September 26, 2037, absent
any available patent term adjustments or extensions;

JP Patent No. 7286658 having
an anticipated expiration date of September 21, 2038, absent any available patent term adjustments or extensions; and

CN Patent No. ZL201880076426.1
having an anticipated expiration date of September 21, 2038, absent any available patent term adjustments or extensions.

Competition

The biotechnology and pharmaceutical
industries have made substantial investments in recent years into the rapid development of novel immunotherapies for the treatment
of a range of pathologies, including cancers, making this a highly competitive market.

We face substantial competition
from multiple sources, including large and specialty pharmaceutical, biopharmaceutical and biotechnology companies, academic research
institutions and governmental agencies, and public and private research institutions. Our competitors compete with us based on the specific
technologies employed, and on the stage of product candidate development. In addition, many small biotechnology companies have formed
collaborations with large, established companies to (i) obtain support for their research, development, and commercialization of
products, or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially
directly compete with our current or future product candidates.

In addition to the current
standard of care treatments for patients with cancer, numerous commercial and academic preclinical studies and clinical trials are being
undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from
these studies and trials have fueled increasing levels of interest in the field of immunotherapy. Accordingly, we face competition from
numerous pharmaceutical and biotechnology entities related to the development of cellular-based therapies to treat cancer. We expect
to face competition from other companies developing TCR T therapies, such as Adaptimmune Therapeutics, plc GlaxoSmithKline plc, MediGene
AG, TCR2 Therapeutics Inc., TScan Therapeutics Inc. and Ziopharm Oncology, Inc. We also may compete with other T cell therapy companies
with target discovery platforms